Giovanni Paganelli, MD
IRST IRCCS, Meldola (FC)
2
1
1
N/A
0
0
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (2)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Alain Hendlisz, MD
Jules Bordet Institute
Shared therapeutic areas:
Urielle Desalbres
AP-HM
Shared therapeutic areas:
George Albert Fisher M.D. Ph.D.
Stanford University
Shared therapeutic areas:
Francois Benard, MD
BC Cancer
Shared therapeutic areas:
Bassel El-Rayes, MD
Emory University Winship Cancer Institute
Shared therapeutic areas:
Steven A Rosenberg, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Neeta Pandit-Taskar, MD
Memorial Sloan Kettering Cancer Center
Shared therapeutic areas:
Brennan Spiegel, MD, MSHS
Cedars-Sinai Medical Center
Shared therapeutic areas:
Xu jianming, M.D.
307 Hospital of PLA
Shared therapeutic areas:
M. Sue O'Dorisio, MD, PhD
University of Iowa
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (2)
Showing 2 of 2 trials
177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine Tumors
Peptide Receptor Radionuclide Therapy With 177Lu-Dotatate Associated With Metronomic Capecitabine In Patients Affected By Aggressive Gastro-Etero-Pancreatic Neuroendocrine Tumors
All 2 trials loaded